Literature DB >> 29259132

Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity.

Jheng-Yu Wu1,2, Shengyan Xiang2, Mu Zhang1, Bin Fang3, He Huang4, Oh Kwang Kwon4, Yingming Zhao4, Zhe Yang5, Wenlong Bai2, Gerold Bepler1, Xiaohong Mary Zhang6.   

Abstract

Histone deacetylase 6 (HDAC6), a class IIb HDAC, plays an important role in many biological and pathological processes. Previously, we found that ERK1, a downstream kinase in the mitogen-activated protein kinase signaling pathway, phosphorylates HDAC6, thereby increasing HDAC6-mediated deacetylation of α-tubulin. However, whether HDAC6 reciprocally modulates ERK1 activity is unknown. Here, we report that both ERK1 and -2 are acetylated and that HDAC6 promotes ERK1 activity via deacetylation. Briefly, we found that both ERK1 and -2 physically interact with HDAC6. Endogenous ERK1/2 acetylation levels increased upon treatment with a pan-HDAC inhibitor, an HDAC6-specific inhibitor, or depletion of HDAC6, suggesting that HDAC6 deacetylates ERK1/2. We also noted that the acetyltransferases CREB-binding protein and p300 both can acetylate ERK1/2. Acetylated ERK1 exhibits reduced enzymatic activity toward the transcription factor ELK1, a well-known ERK1 substrate. Furthermore, mass spectrometry analysis indicated Lys-72 as an acetylation site in the ERK1 N terminus, adjacent to Lys-71, which binds to ATP, suggesting that acetylation status of Lys-72 may affect ERK1 ATP binding. Interestingly, an acetylation-mimicking ERK1 mutant (K72Q) exhibited less phosphorylation than the WT enzyme and a deacetylation-mimicking mutant (K72R). Of note, the K72Q mutant displayed decreased enzymatic activity in an in vitro kinase assay and in a cellular luciferase assay compared with the WT and K72R mutant. Taken together, our findings suggest that HDAC6 stimulates ERK1 activity. Along with our previous report that ERK1 promotes HDAC6 activity, we propose that HDAC6 and ERK1 may form a positive feed-forward loop, which might play a role in cancer.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  acetylation;; enzyme mechanism; histone acetylase; histone deacetylase (HDAC); histone deacetylase 6 (HDAC6); mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase1/2 (ERK1/2)

Mesh:

Substances:

Year:  2017        PMID: 29259132      PMCID: PMC5808760          DOI: 10.1074/jbc.M117.795955

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  A novel class of small molecule inhibitors of HDAC6.

Authors:  Elizabeth S Inks; Benjamin J Josey; Sean R Jesinkey; C James Chou
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

Review 2.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

Review 3.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.

Authors:  X-J Yang; E Seto
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

4.  Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells.

Authors:  Mee-Young Ahn; Ji-Wee Ahn; Hyung-Sik Kim; Jun Lee; Jung-Hoon Yoon
Journal:  Oncol Rep       Date:  2015-02-02       Impact factor: 3.906

Review 5.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

6.  Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes.

Authors:  Vinodkumar B Pillai; Nagalingam R Sundaresan; Sadhana A Samant; Don Wolfgeher; Chinmay M Trivedi; Mahesh P Gupta
Journal:  Mol Cell Biol       Date:  2011-03-28       Impact factor: 4.272

7.  The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain.

Authors:  R Marais; J Wynne; R Treisman
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

8.  Integrated proteomic analysis of post-translational modifications by serial enrichment.

Authors:  Philipp Mertins; Jana W Qiao; Jinal Patel; Namrata D Udeshi; Karl R Clauser; D R Mani; Michael W Burgess; Michael A Gillette; Jacob D Jaffe; Steven A Carr
Journal:  Nat Methods       Date:  2013-06-09       Impact factor: 28.547

9.  An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control.

Authors:  T G Boulton; G D Yancopoulos; J S Gregory; C Slaughter; C Moomaw; J Hsu; M H Cobb
Journal:  Science       Date:  1990-07-06       Impact factor: 47.728

Review 10.  Distinct functions for ERKs?

Authors:  Alison C Lloyd
Journal:  J Biol       Date:  2006
View more
  12 in total

Review 1.  Genetically engineered cellular models of prion propagation.

Authors:  Hamza Arshad; Joel C Watts
Journal:  Cell Tissue Res       Date:  2022-05-18       Impact factor: 5.249

Review 2.  HDAC6: A unique HDAC family member as a cancer target.

Authors:  Sumeet Kaur; Prerna Rajoria; Madhu Chopra
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

3.  Critical review of non-histone human substrates of metal-dependent lysine deacetylases.

Authors:  Tasha B Toro; Terry J Watt
Journal:  FASEB J       Date:  2020-08-30       Impact factor: 5.191

4.  Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy.

Authors:  Jheng-Yu Wu; Niko Moses; Wenlong Bai; Xiaohong Mary Zhang
Journal:  J Immunol Sci       Date:  2018-06-13

5.  Cannabinoid exposure in rat adolescence reprograms the initial behavioral, molecular, and epigenetic response to cocaine.

Authors:  Maria Scherma; Johanna S Qvist; Arun Asok; Shao-Shan C Huang; Paolo Masia; Matteo Deidda; Ya B Wei; Rajesh K Soni; Walter Fratta; Paola Fadda; Eric R Kandel; Denise B Kandel; Philippe A Melas
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-20       Impact factor: 11.205

Review 6.  HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

Authors:  Hélène Losson; Michael Schnekenburger; Mario Dicato; Marc Diederich
Journal:  Cancers (Basel)       Date:  2020-01-29       Impact factor: 6.639

7.  Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor.

Authors:  Husvinee Sundaramurthi; Sandra García-Mulero; Valentina Tonelotto; Kayleigh Slater; Simone Marcone; Josep M Piulats; Ronald William Watson; Desmond J Tobin; Lasse D Jensen; Breandán N Kennedy
Journal:  Cancers (Basel)       Date:  2022-02-03       Impact factor: 6.639

Review 8.  Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma.

Authors:  Husvinee Sundaramurthi; Zoltán Giricz; Breandán N Kennedy
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

Review 9.  Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.

Authors:  Maria Gracia-Hernandez; Zuleima Munoz; Alejandro Villagra
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

10.  HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1.

Authors:  Niko Moses; Mu Zhang; Jheng-Yu Wu; Chen Hu; Shengyan Xiang; Xinran Geng; Yue Chen; Wenlong Bai; You-Wei Zhang; Gerold Bepler; Xiaohong Mary Zhang
Journal:  Cells       Date:  2020-10-04       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.